Fierce Health Payers November 5, 2021
Consolidation among standalone prescription drug plans in Medicare Part D caused offerings to decline by 23% for 2022, a new analysis finds.
The analysis, released earlier this week by the Kaiser Family Foundation, explored the offerings for Part D as open enrollment started last month. But while Part D plan offerings declined, Medicare Advantage plans ballooned by more than double the number of plans available in 2017.
Kaiser’s analysis underscored the need for consumers to shop around, stating that “millions of Part D enrollees without low-income subsidies will face premium and other cost increases in 2022 if they stay in their current stand-alone drug plan,” the analysis said.
There are 766 standalone Part D plans available for consumers for the...
Today's Sponsors
Today's Sponsor